HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)

This study has been completed.
Sponsor:
Collaborators:
St Vincent's Hospital, Sydney
Information provided by (Responsible Party):
Kirby Institute
ClinicalTrials.gov Identifier:
NCT00192660
First received: September 12, 2005
Last updated: April 11, 2012
Last verified: April 2012
  Purpose

This is a prospective, non-randomised, 48 week study of the effect of protease inhibitor (PI) containing and non-PI containing antiretroviral regimens on the expression of adipocyte specific genes, protein levels and cellular structure in HIV-infected individuals, naive to therapy, who are starting therapy for the first time.


Condition Intervention Phase
HIV-Associated Lipodystrophy Syndrome
Cardiovascular Disease
Drug: Lamivudine
Drug: Stavudine
Drug: Didanosine
Drug: Zidovudine
Drug: Tenofovir
Drug: Abacavir
Drug: Efavirenz (EFV)
Drug: Nevirapine
Drug: Indinavir
Drug: Saquinavir
Drug: Amprenavir
Drug: Ritonavir
Drug: Nelfinavir
Drug: Tipranavir
Drug: enfuvirtide (T20)
Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Analysis of Lipodystrophy in HIV-Infected Individuals A Prospective, Non-randomised, 48 Week Study of the Effect of PI Containing and Non-PI Containing Antiretroviral Regimens on the Expression of Adipocyte Specific Genes, Protein Levels and Cellular Structure in HIV-infected Individuals, Naive to Therapy, Who Are Starting Therapy for the First Time

Resource links provided by NLM:


Further study details as provided by Kirby Institute:

Primary Outcome Measures:
  • To investigate changes in adipocyte structure and function in HIV-infected individuals treated with antiretroviral therapy

Secondary Outcome Measures:
  • To correlate changes in adipocyte function with changes in body composition and metabolic parameters in individuals beginning their first antiretroviral regimen
  • To examine changes in adipocyte function in HIV-infected volunteers both prior to and after initiation of treatment in order to determine changes arising directly as a result of therapy
  • To investigate changes in adipocyte function in pre-treated HIV-infected volunteers with and without established signs of HIVLD in order to determine if changes in function correlate with particular phenotypes such as lipoatrophy or buffalo hump

Enrollment: 80
Study Start Date: February 2003
Study Completion Date: December 2007
Primary Completion Date: October 2006 (Final data collection date for primary outcome measure)
Detailed Description:

Antiretroviral medications, used to treat HIV infection, cause side effects. These include changes in composition of fat throughout the body (loss in some areas and accumulation in others), elevations in blood lipids and abnormalities in glucose metabolism. The resulting syndrome is known as "HIV associated lipodystrophy" or HIVLD. In HIV negative populations, such abnormalities in lipid and glucose metabolism are associated with an increased risk of developing cardiovascular disease (CVD). The aim of this study is to characterize the changes that occur in body composition and metabolism with antiretroviral treatment and compare them to changes in fat tissue structure and function and surrogate markers for cardiovascular disease.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age >18.
  • Be able to provide written consent to perform in the trial.
  • HIV antibody positive at time of entry to the study.

Specific to HIV Infection and Metabolic Abnormalities Protocol 1 (HAMA) part A only:

  • Be naive to antiretroviral medication.

Specific to HAMA part B only:

  • Have had a minimum total exposure to antiretroviral medications (to include drugs from more than one drug class) of 48 weeks at time of recruitment.
  • Have had a minimum of 48 weeks interval since completion of HAMA part A.

Exclusion Criteria:

  • Any history of, or ongoing, mental or physical condition (including suspected or known diagnosis of ischaemic heart disease), which, in the opinion of the investigator, would impede the subject's ability to participate in the trial.
  • Prior use of growth hormone or glucocorticoid or anabolic steroid products within the previous six months.
  • Prior use of supraphysiological doses of testosterone or oestrogen replacement therapy within the previous year.
  • Alcohol or substance abuse which in the opinion of the investigator would affect the patients ability to participate in the trial.
  • Prior use of any retinoid-containing compound within the previous six months.
  • Abnormal coagulation.
  • Previous allergic reaction or known allergy to local anaesthetic.
  • Previous or concomitant use of medications, which, in the opinion of the investigator, would affect the subject's ability to participate in all activities involved in the trial.
  • Any grade-three laboratory abnormality recorded from screening bloods, which, in the opinion of the investigator, would impede the subject's ability to safely complete all study requirements.
  • Any finding on screening clinical examination, which, in the opinion of the investigator, would impede the subject's ability to participate in the rest of the trial.
  • Pregnancy

Specific to HAMA part A only:

  • Prior use of anti-retroviral agents (including protease inhibitors, nucleoside or non-nucleoside reverse transcriptase inhibitors, investigational antiretroviral agents or fusion inhibitors). Entry of individuals who have had previous antiretroviral therapy as part of post exposure prophylaxis will be at the discretion of the study investigators.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00192660

Locations
Australia, New South Wales
St. Vincent's Hospital
Sydney, New South Wales, Australia, 2010
Sponsors and Collaborators
Kirby Institute
St Vincent's Hospital, Sydney
Investigators
Principal Investigator: Andrew D Carr, MD St. Vincents Hospital Sydney Limited
Study Director: David A Cooper, MD The National Centre in HIV Epidemiology and Clinical Research, Sydney
  More Information

Additional Information:
No publications provided

Responsible Party: Kirby Institute
ClinicalTrials.gov Identifier: NCT00192660     History of Changes
Other Study ID Numbers: HAMA 001 Version 6, RO1 HL65953-01
Study First Received: September 12, 2005
Last Updated: April 11, 2012
Health Authority: Australia: Department of Health and Ageing Therapeutic Goods Administration

Keywords provided by Kirby Institute:
HIV
Metabolic abnormality
Lipodystrophy
Cardiovascular disease
Treatment Naive
Treatment Experienced
HIV Infections

Additional relevant MeSH terms:
HIV Infections
Cardiovascular Diseases
Lipodystrophy
HIV-Associated Lipodystrophy Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Skin Diseases, Metabolic
Skin Diseases
Lipid Metabolism Disorders
Metabolic Diseases
Didanosine
Zidovudine
Stavudine
Nevirapine
Lamivudine
Tenofovir
Efavirenz
Abacavir
Indinavir
Saquinavir
Ritonavir
Nelfinavir
Enfuvirtide
Amprenavir

ClinicalTrials.gov processed this record on September 14, 2014